BRING DATA
TO LIFE

From trial and error to predictable medicine

BRING DATA
TO LIFE

From trial and error to predictable medicine

THE CYTOREASON DISEASE MODEL

Think of it as the most comprehensive model of human diseases.
Modeling and comparing treatments and patient groups so you get a clear map of disease and drug mechanisms.

MANAGE YOUR DRUG PORTFOLIO

Prioritize all of your programs, compare your treatments to competing treatments, and your drugs across patient populations.

MANAGE YOUR DRUG PORTFOLIO

Prioritize all of your programs, compare your treatments to competing treatments, and your drugs across patient populations.

SEE THE FOREST AND THE TREES

Give your scientist a deep profile of your drug, and your executive a bird’s-eye view of your entire portfolio. One platform for all users.

SEE THE FOREST AND THE TREES

Give your scientist a deep profile of your drug, and your executive a bird’s-eye view of your entire portfolio. One platform for all users.

LISTEN TO LIVING DATA

Base your decisions on the latest human data as your disease models are updated. Use live results to make accurate predictions.

LISTEN TO LIVING DATA

Base your decisions on the latest human data as your disease models are updated. Use live results to make accurate predictions.

KNOW THE RISK AHEAD

Connect molecular mechanisms to your drug’s performance and compare to other drugs in the market. Follow early signals and gain long-term confidence.

KNOW THE RISK AHEAD

Connect molecular mechanisms to your drug’s performance and compare to other drugs in the market. Follow early signals and gain long-term confidence.

In the news

Media Coverage
March 24th, 2022

Poolbeg Pharma signs first of its kind AI deal with CytoReason

Press Release
February 10th, 2022

CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development

Scientific Publications
December 10th, 2021

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial

''

The difference between using CytoReason technology and not using it, is the difference between engineering and art.

''

Mike Vincent

SVP Immunology & Inflammation